Publications

Validation of a TREK diagnostic systems dry-form broth microdilution MIC product for testing ceftazidime-avibactam, Lead author: Jones RN, presented at 114th annual American Society for Microbiology General Meeting (ASM), May 17 – 20, 2014, Boston, MA

Accuracy of Sensititre dry-form broth microdilution panels to determine ceftaroline-avibactam MIC values, Lead author: Jones RN, presented at 114th annual American Society for Microbiology General Meeting (ASM), May 17 – 20, 2014, Boston, MA

Klebsiella pneumoniae belonging to ST258 from a New York city hospital carrying KPC-2- and VIM-4-encoding genes: Report from the SENTRY antimicrobial surveillance program, Lead author: Castanheira M, presented at 114th annual American Society for Microbiology General Meeting (ASM), May 17 – 20, 2014, Boston, MA

Susceptibility testing of isolates displaying elevated colistin MIC values using polysorbate-80 (P-80), Lead author: Castanheira M, presented at 114th annual American Society for Microbiology General Meeting (ASM), May 17 – 20, 2014, Boston, MA

Revised reference broth microdilution method for testing telavancin: effect on MIC results and correlation with other testing methodologies, Lead author: Farrell DJ, presented at 114th annual American Society for Microbiology General Meeting (ASM), May 17 – 20, 2014, Boston, MA

Quality control ranges for performance assessment of a revised broth microdilution susceptibility testing method for telavancin, Lead author: Ross JE, presented at 114th annual American Society for Microbiology General Meeting (ASM), May 17 – 20, 2014, Boston, MA

Ceftobiprole activity tested against bacterial isolates from hospitalized patients with pneumonia in European hospitals and Israel (2013), Lead author: Flamm R, presented at 24th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2014, Barcelona, Spain

Antimicrobial Activity of Ceftobiprole Tested against Staphylococci and Streptococci from European Countries and Israel (2013), Lead author: Flamm R, presented at 24th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2014, Barcelona, Spain

Activity of oritavancin and comparator agents against multidrug-resistant staphylococcal and streptococcal isolates responsible for documented infections in European hospitals (2011-2013), Lead author: Mendes RE, presented at 24th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2014, Barcelona, Spain

Current analysis of oritavancin potency when tested against vancomycin-resistant and -susceptible enterococcal clinical isolates recovered from European medical centres (2009-2013), Lead author: Mendes RE, presented at 24th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2014, Barcelona, Spain

Antimicrobial activity of ceftolozane/tazobactam and comparator agents tested against Enterobacteriaceae isolates from 14 European countries and Israel (2012), Lead author: Farrell DJ, presented at 24th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2014, Barcelona, Spain

Antimicrobial activity of ceftolozane/tazobactam and comparator agents tested against P. aeruginosa isolates from 15 European countries and Israel (2011-2012), Lead author: Farrell DJ, presented at 24th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2014, Barcelona, Spain

Ceftolozane/tazobactam activity when tested against Gram-negative bacterial isolates from hospitalized patients with pneumonia in European hospitals (2011-2012), Lead author: Farrell DJ, presented at 24th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2014, Barcelona, Spain

Ceftazidime-avibactam activity tested against select Gram-negative organisms from a global surveillance program (2011) in relation to the ceftazidime epidemiologic cut-off value, Lead author: Flamm R, presented at 24th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2014, Barcelona, Spain

Telavancin activity against uncommonly isolated Gram-positive pathogens responsible for documented infections in hospitals worldwide (2011-2013) when using a revised susceptibility testing method, Lead author: Mendes RE, presented at 24th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2014, Barcelona, Spain

Global prevalence, genetics and clonal relatedness of macrolide resistance in Moraxella catarrhalis (2010-2012), Lead author: Farrell DJ, presented at 24th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2014, Barcelona, Spain

GSK2140944 MIC quality control ranges using a multi-laboratory study design, Lead author: Jones RN, presented at 24th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2014, Barcelona, Spain

Azole resistance mechanisms found among fluconazole-resistant Candida albicans clinical isolates: Report from the SENTRY antifungal resistance programme, Lead author: Castanheira M, presented at 24th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2014, Barcelona, Spain

KPC-producing Pseudomonas aeruginosa from the United States: What is next?, Lead author: Castanheira M, presented at 24th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2014, Barcelona, Spain

Carbapenem-resistant Klebsiella pneumoniae clinical isolate harbouring a blaIMP-4- and qnrS-carrying plasmid, as well as a conjugative blaKPC-2 plasmid, Lead author: Mendes RE, presented at 24th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2014, Barcelona, Spain

Tigecycline activity tested against carbapenem-resistant Enterobacteriaceae from European hospitals: Results from the SENTRY Program (2010-2013), Lead author: Sader HS, presented at 24th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2014, Barcelona, Spain

Characterization of intrinsic Beta-lactam resistance mechanisms among contemporary ceftazidime non-susceptible Pseudomonas aeruginosa from USA hospitals, Lead author: Castanheira M, presented at 24th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2014, Barcelona, Spain

Evaluation of EUCAST zone diameter breakpoints for Pseudomonas spp., Lead author: Ahman, presented at 24th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2014, Barcelona, Spain

Antimicrobial activity of solithromycin tested against serotyped macrolide-resistant Streptococcus pneumoniae collected from medical centers across the USA (2012), Lead author: Farrell DJ, presented at 24th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2014, Barcelona, Spain

Antimicrobial activity of daptomycin and comparator agents tested against Methicillin-resistant S. aureus and vancomycin-resistant enterococci: Analysis of five-year trends in Europe and USA hospitals (2009-2013), Lead author: Sader HS, presented at 24th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2014, Barcelona, Spain

Serotype distribution and antimicrobial susceptibility of Streptococcus pneumoniae recovered principally from lower respiratory tract specimens in older adult patients (≥50 years of age) in select European countries (2009-2011), Lead author: Mendes RE, presented at 24th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2014, Barcelona, Spain

Activity of oritavancin tested against Gram-positive clinical isolates responsible for documented skin and soft tissue infections in European hospitals (2011-2013), Lead author: Mendes RE, presented at 24th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2014, Barcelona, Spain

Polymyxin B: Can we create a better product?, Lead author: Kassamali, presented at 24th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2014, Barcelona, Spain

Telavancin activity tested against Gram-positive clinical isolates from European hospitals (2011-2013) using a revised broth microdilution testing method: Redefining the baseline activity for telavancin, Lead author: Mendes RE, presented at 24th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2014, Barcelona, Spain

Linezolid susceptibility surveillance in Europe for 2013: ZAAPS Program (5,076 strains), Lead author: Jones RN, presented at 24th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2014, Barcelona, Spain

Multilaboratory study of epidemiological cutoff values for detection of resistance in eight Candida species to fluconazole, posaconazole, and voriconazole. by Espinel-Ingroff A, Pfaller MA, Bustamante B, Canton E, Fothergill A, Fuller J, Gonzalez GM, Lass-Florl C, Lockhart SR, Martin-Mazuelos E, Meis JF, Melhem MS, Ostrosky-Zeichner L, Pelaez T, Szeszs MW, St-Germain G, Bonfietti LX, Guarro J and Turnidge J published in Antimicrob. Agents Chemother. 2014; 58 (4): 2006-2012

Activity of ceftobiprole against methicillin-resistant Staphylococcus aureus (MRSA) strains with reduced susceptibility to daptomycin, linezolid, vancomycin and strains with defined SCCmec types. by Farrell DJ, Flamm RK, Sader HS and Jones RN published in Int. J. Antimicrob. Agents. 2014; 43 (4): 323-327

Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalized with pneumonia in United States and European hospitals: Results from the SENTRY Antimicrobial Surveillance Program, 2009-2012. by Sader HS, Farrell DJ, Flamm RK and Jones RN published in Int. J. Antimicrob. Agents. 2014; 43 (4): 328-334

Frequency of occurrence and antimicrobial susceptibility of gram-negative bacteremia isolates in patients with urinary tract infection: Results from United States and European hospitals (2009-2011). by Sader HS, Flamm RK and Jones RN published in J. Chemother. 2014; 26 (3): 133-138

Activity of ceftaroline and comparator agents tested against contemporary Gram-positive and -negative (2011) isolates collected in Europe, Turkey, and Israel. by Castanheira M, Jones RN and Sader HS published in J. Chemother. 2014; 26 (4): 202-210

Zyvox® Annual Appraisal of Potency and Spectrum (ZAAPS) Program: Report of linezolid activity over 9 years (2004 – 2012). by Mendes RE, Hogan PA, Streit JM, Jones RN and Flamm RK published in J. Antimicrob. Chemother. 2014; 69 (6): 1582-1588

Ceftaroline activity tested against uncommonly isolated gram-positive pathogens: Report from the SENTRY Antimicrobial Surveillance Program (2008- 2011). by Sader HS, Jones RN, Stilwell MG and Flamm RK published in Int. J. Antimicrob. Agents. 2014; 43 (3): 284-286

Post ß-lactamase inhibitor effect of tazobactam in combination with ceftolozane and tested against ESBL-producing strains. by Sader HS, Rhomberg PR and Jones RN published in Antimicrob. Agents Chemother. 2014; 58 (4): 2434-2437

Activity of oritavancin tested against uncommonly isolated Gram-positive pathogens responsible for documented infections in hospitals worldwide. by Mendes RE, Sader HS, Flamm RK and Jones RN published in J. Antimicrob. Chemother. 2014; 69 (6): 1579-1581

Epidemiology and carbapenem resistance mechanisms of carbapenem-non-susceptible Pseudomonas aeruginosa collected during 2009-2011 in 14 European and Mediterranean countries. by Castanheira M, Deshpande LM, Costello A, Davies TA and Jones RN published in J. Antimicrob. Chemother. 2014; 69 (7): 1804-1814

Ceftolozane/tazobactam activity tested against gram-negative bacterial isolates from hospitalized patients with pneumonia in United States and European medical centres (2012). by Farrell DJ, Sader HS, Flamm RK and Jones RN published in Int. J. Antimicrob. Agents. 2014; 43 (6): 533-539

Antimicrobial activity of ceftaroline combined with avibactam tested against bacterial organisms isolated from acute bacterial skin and skin structure infections in United States medical centers (2010-2012). by Flamm RK, Farrell DJ, Sader HS and Jones RN published in Diagn. Microbiol. Infect. Dis. 2014; 78 (4): 449-456

Detection of NDM-1-producing Enterobacteriaceae in Romania: Report of the SENTRY Antimicrobial Surveillance Program. by Deshpande LM, Flonta M, Jones RN and Castanheira M published in J. Med. Microbiol. 2014; 63 (Pt 3): 483-484

Ceftazidime/avibactam activity tested against Gram-negative bacteria isolated from bloodstream, pneumonia, intra-abdominal, and urinary tract infections in United States medical centers (2012). by Flamm RK, Farrell DJ, Sader HS and Jones RN published in J. Antimicrob. Chemother. 2014; 69 (6): 1589-1598

Ceftaroline activity against organisms isolated from respiratory tract infections in USA hospitals: Results from the AWARE Program, 2009-2011. by Flamm RK, Sader HS and Jones RN published in Diagn. Microbiol. Infect. Dis. 2014; 78 (4): 437-442

Use of micafungin as a surrogate marker to predict susceptibility and resistance to caspofungin among 3,764 clinical isolates of Candida using CLSI methods and interpretive criteria. by Pfaller MA, Messer SA, Diekema DJ, Jones RN and Castanheira M published in J. Clin. Microbiol. 2014; 52 (1): 108-114

Variation in potency and spectrum of tigecycline activity against bacterial strains from U.S. medical centers since its approval for clinical use (2006 to 2012). by Sader HS, Farrell DJ, Flamm RK and Jones RN published in Antimicrob. Agents Chemother. 2014; 58 (4): 2274-2280

Resistance surveillance program report for selected European nations (2011). by Jones RN, Flonta M, Gurler N, Cepparulo M, Mendes RE and Castanheira M published in Diagn. Microbiol. Infect. Dis. 2014; 78 (4): 429-436

Contemporary diversity of ß-lactamases among Enterobacteriaceae in the nine United States census regions and ceftazidime-avibactam activity tested against isolates producing the most prevalent ß-lactamase groups. by Castanheira M, Farrell SE, Krause KM, Jones RN and Sader HS published in Antimicrob. Agents Chemother. 2014; 58 (2): 833-838

Frequency of fks mutations among Candida glabrata isolates from a 10-year global collection of bloodstream infection isolates. by Castanheira M, Woosley LN, Messer SA, Diekema DJ, Jones RN and Pfaller MA published in Antimicrob. Agents Chemother. 2014; 58 (1): 577-580